Global Information
회사소개 | 문의 | 위시리스트

과민성 대장 증후군 : 세계 임상시험 리뷰

Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2017

리서치사 GlobalData
발행일 2017년 10월 상품 코드 242604
페이지 정보 영문 355 Pages
가격
US $ 2,500 ₩ 2,919,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,838,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,757,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


과민성 대장 증후군 : 세계 임상시험 리뷰 Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2017
발행일 : 2017년 10월 페이지 정보 : 영문 355 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

과민성 대장 증후군(Irritable Bowel Syndrome) 관련 임상연구의 최신 동향에 대해 분석했으며, 질환 및 치료법 개요, G7 및 E7 국가에서의 임상시험 상황, 지역·상(相)·단계별 진행 상황, 유망한 스폰서, 각 기업 및 연구기관에서의 연구 진행 상황, 유망한 약제 비교 등의 정보를 전해드립니다.

본 보고서의 개요

각 지역에서의 임상시험 상황

  • 각국의 임상시험 건수와 평균 피험자수
    • 주요 5개국에서의 임상시험 건수 : 아시아태평양 지역
    • 주요 5개국에서의 임상시험 건수 : 유럽
    • 주요 국가에서의 임상시험 건수 : 북미
    • 주요 5개국에서의 임상시험 건수 : 중동 및 아프리카 지역
    • 주요 국가에서의 임상시험 건수 : 중남미

G7 국가에서의 임상시험 건수 : 소화관 질환 임상시험 전체에서 과민성 대장 증후군 임상시험 비율

상(相)별 임상시험 건수 : G7 국가

G7 국가에서의 임상시험 건수 : 상(相)별

E7 국가에서의 임상시험 건수 : 소화관 질환 임상시험 전체에서 과민성 대장 증후군 임상시험 비율

상(相)별 임상시험 건수 : E7 국가

E7 국가에서의 임상시험 건수 : 상(相)별

상(相)별 임상시험 건수

  • 상(相)별 진행중인 임상시험 건수

진척 상황별 임상시험 건수

평가 항목별 임상시험 건수

일정기간에 채용된 피험자수

스폰서 종류별 임상시험 건수

유망한 스폰서

임상시험 주요 참여 기업 : 과민성 대장 증후군 치료제

유망한 약제

최신 임상시험 뉴스 : 과민성 대장 증후군

임상시험 프로파일의 기본 정보

부록

도표

LSH 17.03.06

GlobalData's clinical trial report, "Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Irritable Bowel Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Irritable Bowel Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy:

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
    • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Irritable Bowel Syndrome Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Irritable Bowel Syndrome
      • Oct 16, 2017: Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting
      • Oct 16, 2017: Allergan to Present New Data on its Marketed Gastrointestinal Drug Eluxadoline at the World Congress of Gastroenterology at ACG 2017
      • Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
      • Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG 2017
      • Oct 12, 2017: Synergy Pharmaceuticals to Highlight New Data for TRULANCE (Plecanatide) at the World Congress of Gastroenterology at American College of Gastroenterology
      • Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
      • Oct 03, 2017: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D
      • Sep 28, 2017: RedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
  • Source

List of Tables

  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Region, 2017*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries, 2017*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries (%), 2017*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2017*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Phase, 2017*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Irritable Bowel Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures

  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2017*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries (%), 2017*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2017*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2017*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Irritable Bowel Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
  • GlobalData Methodology
Back to Top
전화 문의
F A Q
 
BCC Research